Page last updated: 2024-11-01

nifedipine and Left Heart Hypoplasia Syndrome

nifedipine has been researched along with Left Heart Hypoplasia Syndrome in 1 studies

Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kajimoto, H1
Hashimoto, K1
Bonnet, SN1
Haromy, A1
Harry, G1
Moudgil, R1
Nakanishi, T1
Rebeyka, I1
Thébaud, B1
Michelakis, ED1
Archer, SL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253]Phase 344 participants (Anticipated)Interventional2016-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for nifedipine and Left Heart Hypoplasia Syndrome

ArticleYear
Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction.
    Circulation, 2007, Apr-03, Volume: 115, Issue:13

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Animals, Newborn; Calcium Channel Bl

2007